Ivarmacitinib Sulfate clinical trials
Ivarmacitinib Sulfate is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 2/3. The sponsor with the most trials is Chinese SLE Treatment And Research Group (1). The most-studied condition is Systemic Lupus Erthematosus.
How Ivarmacitinib Sulfate works
All drug targets →- Atopic eczemaPhase 3
- Rheumatoid arthritisPhase 3
- Ankylosing spondylitisPhase 2/3
- Esophageal squamous cell carcinomaPhase 2
- Hepatocellular carcinomaPhase 2
- Triple-negative breast carcinomaPhase 2
- Ulcerative colitisPhase 2
- VitiligoPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5095398, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3), ligand 11878, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Ivarmacitinib Sulfate
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Ivarmacitinib Sulfate
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment
NCT07896096 · ClinicalTrials.gov ↗ · Refractory Metastatic Colorectal Cancer
|
Phase 2 | Recruiting | Renmin Hospital of Wuhan University | China |
|
Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus
NCT07814664 · ClinicalTrials.gov ↗ · Systemic Lupus Erthematosus
|
Phase 2/3 | Not yet open | Chinese SLE Treatment And Research Group | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Ivarmacitinib Sulfate
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Chinese SLE Treatment And Research Group | 1 |
| Renmin Hospital of Wuhan University | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Ivarmacitinib Sulfate trials
How many clinical trials are testing Ivarmacitinib Sulfate?
2 current trials in our China register name Ivarmacitinib Sulfate as a drug or biological intervention, as of the registry sync on 29 October 2026. Completed and withdrawn studies are not counted.
Are Ivarmacitinib Sulfate trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Ivarmacitinib Sulfate clinical trials?
Chinese SLE Treatment And Research Group (1) and Renmin Hospital of Wuhan University (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ivarmacitinib Sulfate works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ivarmacitinib Sulfate works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ivarmacitinib Sulfate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.